Literature DB >> 8422665

Effects of natural interferon alpha, natural tumor necrosis factor alpha and their combination on human mesothelioma xenografts in nude mice.

T Ohnuma1, L Szrajer, J F Holland, M Kurimoto, J Minowada.   

Abstract

Effects of human natural interferon alpha (nIFN) alone, human natural tumor necrosis factor alpha (nTNF) alone and their combination (OH-1) were tested on three human mesothelioma lines implanted in nude mice. Tumors were transplanted subcutaneously by trocar on treatment day -12. nIFN was given intraperitoneally (i.p.) at a dose of 2 x 10(7) or 2 x 10(8) IU kg-1 day-1, 5 days a week for 3 weeks. nTNF was given i.p. at a dose of 2 x 10(7) or 2 x 10(8) U kg-1 day-1 in the same schedule as that of nIFN. Tumor diameters were serially measured and tumor volumes were calculated. Antitumor effects were assessed by two methods: comparison of final tumor volumes in treated and control groups (T/C), and changes in median average total tumor volume. The treatment produced no clinically discernible toxicities. nIFN had strong inhibitory activity against all three human mesothelioma lines. nTNF alone had modest activity only at the high dose used. The combination of the two produced activity essentially similar to that produced by nIFN alone. High-dose nIFN may have a role as an active agent in the treatment of patients with mesothelioma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8422665     DOI: 10.1007/bf01789128

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

1.  Nonrandom chromosome alterations in human malignant mesothelioma.

Authors:  N C Popescu; A P Chahinian; J A DiPaolo
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

Review 2.  Current concepts: malignant mesothelioma.

Authors:  K H Antman
Journal:  N Engl J Med       Date:  1980-07-24       Impact factor: 91.245

Review 3.  The pathogenesis of asbestos-associated diseases.

Authors:  J E Craighead; B T Mossman
Journal:  N Engl J Med       Date:  1982-06-17       Impact factor: 91.245

Review 4.  Drug therapy: antiviral agents (second of two parts).

Authors:  M S Hirsch; M N Swartz
Journal:  N Engl J Med       Date:  1980-04-24       Impact factor: 91.245

5.  Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers.

Authors:  A S Alberts; G Falkson; L Goedhals; D A Vorobiof; C A Van der Merwe
Journal:  J Clin Oncol       Date:  1988-03       Impact factor: 44.544

6.  Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon.

Authors:  B B Aggarwal; T E Eessalu; P E Hass
Journal:  Nature       Date:  1985 Dec 19-1986 Jan 1       Impact factor: 49.962

7.  Simultaneous production of natural human tumor necrosis factor-alpha, -beta and interferon-alpha from BALL-1 cells stimulated by HVJ.

Authors:  S Fukuda; S Ando; O Sanou; M Taniai; M Fujii; N Masaki; K Nakamura; O Ando; K Torigoe; T Sugimoto
Journal:  Lymphokine Res       Date:  1988

8.  Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice.

Authors:  K Haranaka; N Satomi; A Sakurai
Journal:  Int J Cancer       Date:  1984-08-15       Impact factor: 7.396

9.  Chemotherapy of human tumor xenografts in genetically athymic mice.

Authors:  A A Ovejera; D P Houchens; A D Barker
Journal:  Ann Clin Lab Sci       Date:  1978 Jan-Feb       Impact factor: 1.256

10.  Phase I study of recombinant tumor necrosis factor in cancer patients.

Authors:  M Blick; S A Sherwin; M Rosenblum; J Gutterman
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

View more
  1 in total

1.  High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma.

Authors:  M Halme; A Knuuttila; T Vehmas; L Tammilehto; M Mäntylä; J Salo; K Mattson
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.